Suicidal risk during treatment with clozapine: a meta-analysis.

Author: BaldessariniRoss J, HennenJohn

Paper Details 
Original Abstract of the Article :
Suicide remains a major cause of premature mortality among patients with schizophrenia. Evidence of reduced suicidal risk with available psychiatric treatments is limited, but emerging data suggest such an effect of clozapine in chronically psychotic patients, leading us to compile the reported evid...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.schres.2004.05.015

データ提供:米国国立医学図書館(NLM)

Clozapine: A Potential Benefit for Reducing Suicidal Risk in Schizophrenia

This meta-analysis examined the association between clozapine treatment and suicidal risk in patients with schizophrenia. The authors compiled data from multiple studies, assessing the potential benefits of clozapine in reducing suicidal risk in chronically psychotic patients.

Clozapine's Potential Benefits

The meta-analysis suggests that clozapine may be associated with a reduced suicidal risk in patients with schizophrenia. These findings provide evidence for the potential benefits of clozapine in managing this serious mental health condition.

Managing Mental Health

This research emphasizes the importance of ongoing research into the treatment of schizophrenia, particularly in relation to suicidal risk. The findings highlight the potential role of clozapine in managing this complex condition and improving patient outcomes.

Dr.Camel's Conclusion

Just as a camel navigates the unpredictable desert landscape, we must approach mental health challenges with careful consideration. This meta-analysis suggests that clozapine may offer a potential benefit for reducing suicidal risk in schizophrenia, providing hope for improved outcomes for patients.

Date :
  1. Date Completed 2005-06-09
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

15653256

DOI: Digital Object Identifier

10.1016/j.schres.2004.05.015

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.